Celanese Co. (NYSE:CE) has been granted a Brokerage Consensus Recommendation of 'Hold'. The corporation and
Mitsubishi Gas have signed an MOU, while further actions to expand their design materials capacity in Asia are underway. Meanwhile, various financial institutions, including
Nomura Holdings, Czech National Bank, Virtu Financial, and Vanguard Group, have either acquired, increased or lowered their share holdings in CE. In terms of recent financial performance, the stock of Celanese Corp has underperformed on certain days compared to competitors, but it has also seen growth of 39% in the past 6 months. The corporation's first-quarter earnings missed EPS estimates but reported incremental revenue growth. Despite challenges, the corporation reported robust cash flow and deleveraging in 2024 and achieved milestones in their acetyl chain business. Furthermore, they formed a partnership with Glaukos for glaucoma treatment, and with Secarna for antisense therapies. Force majeure has been declared due to supply disruptions in the western hemisphere for acetic acid and VAM. The company's dividend has been set at $0.70, with CE outperforming despite losses on certain days. Overall, while bearing some risks, CE provides a long-term value investment prospect.
Celanese Corporation CE News Analytics from Fri, 08 Dec 2023 08:00:00 GMT to Sun, 23 Jun 2024 18:53:44 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -1
